

ಕರ್ನಾಟಕ ಸರ್ಕಾರ

ಸಂಖ್ಯೆ: ಆಕುಕ 107 ಅಮುಕಾ 2021

ಕರ್ನಾಟಕ ಸರ್ಕಾರ ಸಚಿವಾಲಯ ವಿಕಾಸ ಸೌಧ ಬೆಂಗಳೂರು, ದಿನಾಂಕ: 20.04.2021

ಸುತ್ತೋಲೆ

ಕೋವಿಡ್–19 ರೋಗಿಗಳಗೆ ಚಿಕಿತ್ಸೆ ನೀಡಲು ಅನುಸರಿಸಬಹುದಾದ ಚಿಕಿತ್ಸಾ ಮಾರ್ಗಸೂಚಿ – Guidelines for Management of COVID-19 -A point of Care Approach (Version 4.0) ನ್ನು ಡಾ: ಎಸ್.ಸಚ್ಚಿದಾನಂದ್ ರವರ ಅಧ್ಯಕ್ಷತೆಯಲ್ಲನ ಕ್ಲಿನಿಕಲ್ ಪ್ರೊಟೊಕಾಲ್ ಸಮಿತಿ ಹಾಗೂ ಡಾ: ಎಂ.ಕೆ.ಸುದರ್ಶನ್ ಇವರ ಅಧ್ಯಕ್ಷತೆಯಲ್ಲನ ತಾಂತ್ರಿಕ ಸಲಹಾ ಸಮಿತಿಯು ಜಂಚಿಯಾಗಿ ಅನುಮೋದಿಸಿರುತ್ತದೆ (ಪ್ರತಿ ಲಗತ್ತಿಸಿದೆ).

ಸದರಿ Guidelines for Management of COVID-19 (Version 4.0) ನ್ನು ಅನುಸರಿಸಲು ಕೋರಿದೆ.

pages-1to17

್ಷು ನ್ನಿ ನ್ನ (ಜಾವೇದ್ ಅಖ್ತರ್)

ಸರ್ಕಾರದ ಅಪರ ಮುಖ್ಯ ಕಾರ್ಯದರ್ಶಿ ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣ ಇಲಾಖೆ

ಇವರಿಗೆ:

- 1. ಸರ್ಕಾರದ ಪ್ರಧಾನ ಕಾರ್ಯದರ್ಶಿ, ವೈದ್ಯಕೀಯ ಶಿಕ್ಷಣ ಇಲಾಖೆ
- 2. ಆಯುಕ್ತರು, ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣ ಸೇವೆಗಳು, ಬೆಂಗಳೂರು
- 3. ಮುಖ್ಯ ಆಯುಕ್ತರು, ಜಿ.ಜಿ.ಎಂ.ಪಿ.
- 4. ಅಭಿಯಾನ ನಿರ್ದೇಶಕರು, ರಾಷ್ಟ್ರೀಯ ಆರೋಗ್ಯ ಅಭಿಯಾನ, ಬೆಂಗಳೂರು
- 5. ಎಲ್ಲಾ ಜಿಲ್ಲಾಧಿಕಾರಿಗಳು/ಜಿಲ್ಲಾ ಪಂಚಾಯಿತಿಗಳ ಎಲ್ಲಾ ಮುಖ್ಯ ಕಾರ್ಯನಿರ್ವಹಣಾಧಿಕಾರಿಗಳು
- 6. ಕಾರ್ಯಕಾರಿ ನಿರ್ದೇಶಕರು, ಸುವರ್ಣ ಆರೋಗ್ಯ ಸುರಕ್ತಾ ಟ್ರಸ್ಟ್
- 7. ನಿರ್ದೇಶಕರು, ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣ ಸೇವೆಗಳು, ಬೆಂಗಳೂರು
- 8. ನಿರ್ದೇಶಕರು, ವೈದ್ಯಕೀಯ ಶಿಕ್ಷಣ, ಬೆಂಗಳೂರು
- 9. ಖಾಸಗಿ ವೈದ್ಯಕೀಯ ಕಾಲೇಜುಗಳ ಎಲ್ಲಾ ನಿರ್ದೇಶಕರುಗಳು ಮತ್ತು ವೈದ್ಯಕೀಯ ಅಧೀಕ್ಷಕರುಗಳು
- 10. ಎಲ್ಲಾ ಜಿಲ್ಲಾ ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣಾಧಿಕಾರಿಗಳು / ಎಲ್ಲಾ ಜಿಲ್ಲೆಯ ಜಿಲ್ಲಾ ಶಸ್ತ್ರಚಿಕಿತ್ಸಕರು/ಜಿಲ್ಲಾ ಸರ್ವೇಕ್ಷಣಾಧಿಕಾರಿಗಳು

ಪ್ರತಿಯನ್ನು:

- 1. ಕರ್ನಾಟಕ ಸರ್ಕಾರದ ಮುಖ್ಯ ಕಾರ್ಯದರ್ಶಿ ಇವರ ಆಪ್ತ ಕಾರ್ಯದರ್ಶಿಗಳು
- 2. ಮಾನ್ಯ ಸಚಿವರು,ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣ ಇಲಾಖೆ & ವೈದ್ಯಕೀಯ ಶಿಕ್ಷಣ, ಇವರ ಆಪ್ತ ಕಾರ್ಯದರ್ಶಿಗಳು

Guidelines for Management of COVID19

[A Point of Care Approach]


Version 4.0 (POC)

April 2021

Government of Karnataka

0.

HOME ISOLATION



Asymptomatic: COVID-19 Positive COVID-19 Positive with Mild Symptoms

- Anosmia
- Fever
- · Dry Cough
- Myalgia
- Diarrhoea
- · Loss of Taste/smell

Investigations Suggested:

- CBC, LFT, RFT
- RBS
- CXR

CRP

- SpO2 monitoring 6 hourly
- 6MWT(Six Minute Walk Test) or 3MWT (For >60 yrs.)

Management:

T. Ivermectin 12mg OD for 3 daysOR
 T.Favipiravir 1800mg (200mg ×9) BD on Day 1,
 f/b 800mg(200mg ×4) BD For 6 days.

Once

- T. Vitamin C 500mg BD
- T. Zinc 50mg OD

Monitor Symptoms and Body Temperature Maintain Adequate Hydration

Monitor Oxygen saturation with a Pulse Oximeter

Measure BP twice a day

Perform 6MWT everyday

If the Above patients Develops these symptoms/signs:

- Shortness of Breath/Breathlessness
- Resting Heart Rate >100/Palpitations
- SpO2 <94% on any occasion
- 6MWT/3MWT induced Desaturation of >4%
- Neutrophil Lymphocyte Ratio>3.5
- · Worsening of Symptoms

To be shifted immediately to DCHC/DCH.

Eligibility for Home Isolation/Home care:

- The person shall be clinically assigned as asymptomatic/mild case through telephonic triage or by the health staff/medical officer/ physician. Such cases should have the requisite facility at their residence for self-isolation and also for quarantining the family contacts.
- A caregiver should be available to provide care on a 24 X 7 basis. A regular communication link between the caregiver and hospital is a prerequisite for the entire duration of home isolation/ home care
- The person shall provide a signed undertaking for self-isolation/home care and follow guidelines of home isolation/home care
 The person shall agree to monitor his/her health and regularly inform their health status to the telemonitoring team/ medical officer/physician/ family doctor and District Surveillance Officer (DSO) for further follow up by the surveillance teams.
 - Home isolation/home care shall not be applicable for pregnant women 2 weeks before expected date of delivery (EDD)

 All opting for Home isolation should have Pulse Oximeter and BP Apparatus at home.



 Patient Who symptoms increase within the next 12-24 hours, needs to be Shifted to CCC/DCHC depending on situation

COVID CARE CENTRES (CCC)

Separate well ventilated room with a separate toilet for the person in isolation/home care.

The person shall stay in the identified room and away from other persons in the home. Group A/B, with no adequate facilities for proper Home Isolation will be in CCC

Investigations:

- CBC, LFT, RFT
- RBS
- Chest Xray
- CRP
- SpO2 monitoring 6 hourly
- 6MWT (Six-minute Walk Test) /3MWT

Once

Any Desaturation >4% on 6MWT is an indication to shift to DCHC/DCH immediately.

Management:

- T. Ivermectin 12mg OD for 3 daysOR
 T.Favipiravir 1800mg (200mg ×9) BD on Day 1, f/b 800mg (200mg ×4) BD for 6 days
- T. Vitamin C 500mg BD
- T. Zinc 50mg OD

Monitor Symptoms and Body Temperature

Monitor Oxygen saturation

Maintain Adequate Hydration/ Drink Plenty of Fluids

Monitor Oxygen saturation with a Pulse Oximeter

Measure BP twice a day

Perform 6MWT everyday

Supportive Counselling of the Patient & family members

If the Above patients Develops these symptoms/signs:

- Shortness of Breath (Breathlessness)
- Resting Heart Rate >100, Palpitations
- SpO2 <94% on any occasion
- 6MWT induced Desaturation of >4%
- Neutrophil Lymphocyte Ratio >3.5
- Worsening of Symptoms

To be shifted immediately to DCHC/DCH

50% of beds in CCCs should have facility for Oxygen Supply

Availability of BP Apparatus and Pulse Oximeters is a Must.



Patient in CCC will stand discharged /released from home isolation):

- after 10 days of symptom onset (or date of sampling, for asymptomatic cases)
 and
- no fever for 3 days consecutive,
- Maintains oxygen saturation above 94;

Thereafter, the patient shall be advised to isolate at home and self-monitor their health for further 7 days.

There is no need for any COVID-19 test (RT-PCR / CBNAAT /True-NAT/Rapid Antigen Test) after the period of home isolation is over.

Designated COVID Health Centres (DCHC)

Symptomatic Patients with Comorbidities

- Age >60
- Obesity
- DM/HTN/IHD
- COPD/Chronic Lung Disease
- Immunosuppressed State
- CKD / CLD

Investigations:

- CBC
- LFT
- RFT
- RBS
- ECG
- Chest Xray
- SpO2
- 6MWT/3MWT
- HRCT Thorax (If Available)
- CRP
- D-Dimer

Management:

- T. Ivermectin 12mg OD for 3 daysOR
 T.Favipiravir 1800mg (200mg ×9) BD on Day 1, f/b 800mg (200mg ×4) BD for 6 days
- T. Vitamin C 500mg BD
- T. Zinc 50mg OD
- Inj. LMWH [E.g., Enoxaparin 0.5mg/kg/day] S/C or Inj.Heparin 5000U, if D-Dimer >1000ng/ml for 7 days.
- Start on Oxygen therapyimmediatelyif Saturation drops <94%,

Blood tests to be

repeated after 72

hours, if baseline values are abnormal.

Add Inj. Dexamethasone 6mg IV OR T. Dexamethasone 8mgOD for 5-10 days

Monitor Symptoms and Body Temperature

Monitor Oxygen saturation

Adequate Control and Management of Comorbidities

C

Antibiotics if Clinical Signs of Bacterial Infection
Supportive Counselling of the Patient & family members

Patient to be shifted to DCH if: Any Desaturation <90%, Any Uncontrolled Comorbidities, Any Neutrophil Lymphocyte Ratio >17 Any Worsening of Symptoms

Use Inj.Remdesivir only in patients with duration of symptoms <10 days.(Ideally <5days) so as to STRIKE EARLY and STRIKE HARD

Designated COVID Hospitals (DCH)- Wards



Pneumonia without Respiratory Failure

Investigations:

- SpO2
- CBC
- LFT
- RFT
- ECG

RBS

- CXR
- CRP, D-Dimer
- LDH, Ferritin
- ABG baseline
- Triglycerides
- Procalcitonin
- HRCT Thorax
- Trop-I, CKMB
- IL-6

Blood tests to be repeated after 48 hours, if baseline values are abnormal.

ROX INDEX

Ratio of SpO2/FiO2 to Respiratory rate:

<4.8 is an indication to shift to ICU

Management:

- Inj. LMWH [E.g., Enoxaparin 0.5mg/kg/day]S/C or Inj. Heparin 5000U IV TID if D-Dimer >1000ng/ml for 7 days/ till discharge if values of D-Dimer is still high >500.
- If CRP is elevated, Steroids can be Considered
 - Inj. Methylprednisolone 40mg IV [1-2mg/kg] for 5-10 daysOR
 - Inj. Dexamethasone 6mg IV [0.2-0.4mg/kg]OR
 - T. Dexamethasone 8mg OD for 5-10 days
- Inj. Remdesivir 200mg IV OD on D1, F/b 100mg IV OD for 4 days
- T. Vitamin C 500mg BD
- T. Zinc 50mg OD
- Start on Oxygen therapy if Saturation drops <94%.

3

- Pulmonary Rehabilitation Exercises to be initiated
- Supportive Counselling of the Patient & family members

Monitor Symptoms and Body Temperature Monitor Oxygen saturation Adequate Control and Management of Comorbidities

Antibiotics if Clinical Signs of Bacterial Infection

Danger Signs:

- SpO2 <90% on any occasion, PaO2 <60mmHg
- Neutrophil Lymphocyte Ratio>17

Designated COVID Hospitals (DCH)- Wards

Pneumonia with Respiratory Failure

E

Investigations:

- SpO2
- CBC
- LFTRFT
- 1/1 1
- RBSECG
- CXR
- CRP,D-Dimer
- LDH, Ferritin
- ABG as required
- Triglycerides
- Procalcitonin
- HRCT Thorax
- Trop-I
- CK-MB
- IL-6

Management:

- Oxygen Therapy as Appropriate
- CARP(COVID19 Awake Repositioning-Proning) Protocol
- Inj. Methylprednisolone 40mg IV [1-2mg/kg] for 5-10 days OR

Blood tests to be

repeated after 48

hours

- Inj. Dexamethasone 6mg IV [0.2-0.4mg/kg] for 5-10 days
- Inj. LMWH [E.g., Enoxaparin 0.5mg/kg/day] S/C or Inj. Heparin 5000 IU IV TID till the patient is discharged/ D-dimer levels <500ng/dl
- Inj. Remdesivir 200mg IV OD on D1, F/b 100mg IV OD for 4 days.

ROX INDEX

Ratio of SpO2/FiO2 to Respiratory rate:

<4.8 is an indication to shift to ICU



- Consider Use of Convalescent Plasma Therapy, 4-13ml/kg (Usually 200ml single dose is given slowly over not less than 2 hours) if Patient continues to be hypoxic when still on Antivirals; Not recommended after 6th day of illness.
- T. Vitamin C 500mg BD
- T. Zinc 50mg OD

Adequate Control and Management of Comorbidities

Antibiotics if Clinical Signs of Bacterial Infection

Pulmonary Rehabilitation Exercises to be initiated

Supportive Counselling of the Patient & family members

Danger Signs:

- SpO2 <90% on any occasion, PaO2 <60mmHg
- Neutrophil Lymphocyte Ratio >17

Designated COVID Hospitals (DCH)- ICU



Pneumonia with Respiratory Failure with Sepsis /Septic Shock/Multi Organ Dysfunction Syndrome

- SpO2 <90 on Room Air
- RR>30/min
- PaO2 <60mmHg
- Altered Mental Status
- Any Sign of End Organ Damage

Investigations:

- CBC, LFT, RFT
- RBS
- ECG
- CXR
- CRP, D-Dimer
- LDH, Ferritin
- ABG as needed
- Triglycerides
- Procalcitonin
- HRCT Thorax
- Trop-I, CK-MB
- IL-6
- Blood Culture

Management:

- Oxygen Therapy and Airway Management as Appropriate
- CARP (COVID Awake Repositioning Proning) Protocol
- Initiate Antibiotics as per Institution Protocol, Ideally within 1 hour of Admission.
- Inj. LMWH [E.g., Enoxaparin 0.5mg/kg/dayBD] S/C or Inj. Heparin 5000U IV TID until discharge.

Blood tests to be repeated after 48 hours/ As indicated.

- Inj. Methylprednisolone 40mg [1-2mg/kg] IV for 5-10 daysOR
 Inj. Dexamethasone 6mg IV [0.2-0.4mg/kg] for up to 10 daysOR
 Inj. Hydrocortisone 50mg TiD for up to 10 days OR
 Tab. Prednisolone 40mg ODOR
- Tab. Methylprednisolone 16mg BD or 8mg QiD
 Consider use of Inj. Tocilizumab 400mg[8mg/kg] IV in 100ml NS over 1 hour, 12 hours apartOR
 - Inj. Itolizumab Up to 1.6 mg/kg IV, to be given in 250 ml normal saline over 6 hours, Single dose: If Patient continues to be hypoxic in spite of Higher Respiratory Support.
- T. Vitamin C 500mg BD
- T. Zinc 50mg OD

Continuous Monitoring of Vital parameters
Adequate Control and Management of Comorbidities
Pulmonary Rehabilitation Exercises to be initiated
Supportive Counselling of family members
Cardiac Monitoring and MR-Scanning for Myocarditis

RED FLAG SIGNS:

- SpO2 <90% on any occasion
- Neutrophil Lymphocyte Ratio >17

Investigations to be repeated as and when appropriate, Decisions to be individualised to each patient

All the decisions to be taken on the basis of Clinical Signs and Symptoms, rather than Blood and Radiological parameters

VENTILATION IN PATIENTS WITH ARDS WITH LOW LUNG COMPLIANCE:

- Select volume A/C mode on the ventilator
- Set ventilator settings to achieve initial VT = 6 mL/kg PBW.
- Set initial rate to approximate baseline minute ventilation (not >35 bpm).
- Aim for a pH over 7.2, do not worry about the PaCO2. If the PaCO2 keeps going up too much in spite of a RR of 35, reduce the dead space in the circuit. If the pH drops below 7.2, consider adding sodium bicarbonate infusion.
- Use a minimum positive end expiratory pressure (PEEP) of 5 cm H2O.
- Plateau pressure goal: ≤30 cm H2O
- Check Pplat (0.5 second inspiratory pause) at least every 4 hours and after each change in PEEP or VT
- If the Pplat remains above 30 cm H2O, decrease VT by 1 mL/kg steps (minimum = 4 mL/kg).

VENTILATION IN PATIENTS WITH ARDS WITH NEAR-NORMAL LUNG COMPLIANCE:

- · Select volume A/C mode on the ventilator
- PEEP <10 cm of water with BP monitoring
- FIO2 < 60 70% to keep SaO2 > 85, PaO2 < 60 mmhg
- Tidal volume 8-10 ml/kg
- · Prone ventilation not indicated
- · Try semi recumbent position
- Try weaning slowly, watch for mucosal oedema, Hydrocortisone 200 mg IV, 30min before extubating.

Monitoring in COVID-19

<u>Parameters</u>	<u>A</u>	<u>B</u>	<u>c</u>	D	<u>E</u>	<u> </u>
BP, Heart Rate	Daily	Daily	12 hrly	6 hrly	6 hrly	Continuously
SpO2	6 hrly	6 hrs	4 hrly	4 hrly	Continuously /2hrly	Continuously
CBC, RFT. LFT, CRP	Once	Once	Every 2 days	Every 2 days	Every 2 days	Daily
D-Dimer	-	DEA	Once/ As indicated	Every 2 days	Every 2 days	Every 2 days
ECG	Once	Once	Once/As Indicated	Every 2 days	Every 2 days	Daily
ABG	-	entra e	Once if Indicated	Every 2 days	Daily	Daily/ As Indicated
Chest Xray	Once	Once	Once/ As Indicated	Every 2 days	Every 2 days/ As Indicated	As indicated/every 2 days

The Decisions of Management should be on the basis of Clinical Judgement rather than the Radiological and Haematological Parameters



PULMONARY REHABILITATION

Frequency of exercises

1st Week – One full sequence of below (1-8) exercises to be done only once. Repeat 4 times/day with minimum interval of 2-3hrs

 2^{nd} week – one full sequence of below (1-8) exercises to be done twice. Repeat 3 times/day 3^{rd} & 4^{th} week - one full sequence of below (1-8) exercises to be done thrice. Repeat 2 times/day

- 1. Diaphragmatic Breathing.
- 2. Incentive Spirometry.
- 3. Sit to Stand Squats.
- 4. Stand Marching.
- 5. Seated Arm Reaches.
- 6. Standing Heel Raises.
- 7. Side stepping.
- 8. Wall Push-Ups.

Do not proceed if you do not feel well enough to exercise. STOP exercise immediately if you get chest pain, palpitations, exhaustion, or dizziness/lightheadedness.

OXYGEN THERAPY TITRATION

TARGET SATURATION (with lowest FiO2 possible)

All COVID19 patients: SpO2 94-96% COVID19 patients with COPD: SpO2 88-92%

For Patients on Mechanical Ventilation: SpO2 90-92%

Nasal Canula Up to 6L/min

Face Mask Up to 12L/min

Non Rebreathing Mask up to
15L/min

High Flow Nasal Canula

Non Invasive Ventilator

Invasive Mechanical Ventilator

Allow at least 5 mins at each dose before adjusting further upwards or downwards (except with Major and sudden fall in saturation − falls ≥ 3% also require clinical review)

MANAGEMENT OF HYPERTENSION IN COVID 19 PNEUMONIA

Among patients with COVID 19, studies have shown that concomitant hypertension is an independent risk factor carrying a twofold mortality risk as compared to non-hypertensives. Hypertension, CKD, AKI, ESRD patients on maintenance haemodialysis and ischemic heart disease with or without diabetes are the array of patients with COVID 19 and hypertension. Hence the patients with co morbidities are expected to have severe forms of COVID 19. There is no evidence that stopping the antihypertensive reduces severity of COVID 19. Studies on hypertensives with COVID 19 using RAAS antihypertensive and non RAAS antihypertensive like beta blockers and calcium channel blockers showed no difference in disease severity, but lower mortality among patients using RAAS agents have been documented.

Patients with AKI not requiring dialysis should be managed with conservative fluid resuscitation goals. Since more patients may in addition have pneumonia and ARDS limiting the use of iv fluids, fluid resuscitation should be individualized based on trackable objective measures like IVC collapse in bedside USG.

For ESRD/CKD and AKI patients requiring RRT, the indications remain the same as for non-COVID patients.

Investigations recommended for hypertensives with COVID 19:

- ECG/ 2D ECHO is possible
- BNP, Troponin I, CPK-MB
- RFT/urine routine
- Serum electrolytes
- · Cardiac monitoring for arrhythmias
- USG abdomen/chest
- MR scanning for myocarditis.

All COVID 19 patients presenting with hypertension BP>140/90, / SBP>160 mmHg

- 1. With history of hypertensive drugs for same- to continue, if well controlled.
- 2. Diabetics if on ACE inhibitors or ARBs to continue.
- 3. CKD/ESRD on HD to continue same antihypertensive closely monitoring RFT and serum electrolytes/ RRT continued.
- 4. If AKI suspected- urine routine for proteinuria, haematuria, abnormal RFT.

3

- Monitor input/output chart
- Avoid ACE inhibitors and ARBs. Use non RAAS antihypertensives.
- Daily monitoring of serum creatinine and serum electrolytes.
- · Avoid nephrotoxic drugs.
- If associated diabetes mellitus present or steroid used for ARDS COVID 19 regimen, monitor blood sugars
- Check for procalcitonin.

MANAGEMENT OF HYPERGLYCEMIA AND DIABETES IN COVID19

Ref: ENDOCRINOLOGY IN THE TIME OF COVID-19: Remodelling diabetes services and emerging innovationin European Journal of Endocrinology, August 2020

Where change seen	Key difference with COVID-19	Suggested action		
Early in admission	People with COVID-19 infection appear to have a greater risk of hyperglycemia with ketones including: • People with type-2 diabetes (risk even greater if on a SGLT-2 inhibitor) • People with newly diagnosed diabetes Covid-19 disease precipitates atypical presentations of diabetes emergencies (e.g. Mixed DKA and hyperosmolar states)			
Severe illness on admission	Fluid requirements may differ in those with DKA/HHS and evidence of : or "Lung leak" myocarditis	 After restoring the circulating volume the rate of fluid replacement regimen may need to be adjusted where evidence of "lung leak" or myocarditis. Contact the diabetes specialist team early Early involvement of the critical care team 		
All inpatient areas	Infusion pumps may not be available to manage hyperglycemia using intravenous insulin as these are required elsewhere (e.g. for sedation in ICU)	 Use alternative s/c regimens to mange Hyperglycemia Mild DKA Contact the diabetes specialist team for support 		
ICU	Significant insulin resistance seen inpeople with type-2 diabetes in ICU settings	 IV insulin protocols may be need amending (people seen requiring up to 20 units/hr) Patients often nursed prone to feeding may be accidentally interrupted – paradoxical risk of hypoglycemia 		

1: People with no past history of Diabetes and no Stress Hyperglycaemia:

Blood Glucose Monitoring:

Frequency: Two tests per day – at least

Timings: Fasting; Before and 2 hours After Meals

Blood Glucose Targets mg/dl: Pre-meal= 80 to 120; Post-meal= 140 - 180

Special Note: Even if initial blood glucose levels are normal, repeat frequent daily

monitoring should be done if started on steroids.

2: People with no past history of Diabetes; Stress Hyperglycaemia diagnosed in Hospital:

Blood Glucose Monitoring:

Frequency: Four to six tests per day

Timings: Fasting; Before and 2 hours After Meals; 3 am

Blood Glucose Targets mg/dl: Pre-meal= 80 to 120; Post-meal = 140 – 180

Special Note: More frequent daily monitoring should be done if started on steroids.

Oral Diabetes Medications

Start the following new diabetes medications:

Always try to include Gliptins [DPP4 Inhibitors] in the treatment regimen [Eg: Tab

Vildagliptin / Sitagliptin] at the appropriate doses

Insulin Injections: Please enter details in the Diabetes Monitoring Sheet

Start the following new insulin regimen Bolus Only:

Insulin Regular Scheduled [Fixed] Dose TID + Sliding Scale Dose TID [Before Breakfast, Lunch and Dinner

[Choose the appropriate Sliding Scale: Low - Mid - High]

Sliding Scale Choices Insulin Units:			TDD= Total Daily Dose given on previous day				
TDD	Scale	BG < 150	151-200	201-250	251-300	> 300	
< 40	Low	0	2	4	6	8	
41-80	Mid	0	3	6	9	12	
> 80	High	0	4	8	12	16	

Dose Titration: Daily calculate the Total Daily Dose of Insulin [TDD] and upgrade or downgrade the Scheduled Insulin Doses

3: People with past history of Diabetes on Oral Diabetes Medicines OHA [+/- Insulin]:

Blood Glucose Monitoring:

Frequency: Four to six tests per day

Timings: Fasting; Before and 2 hours After Meals; 3 am

Blood Glucose Targets mg/dl: Pre-meal= 80 to 120; Post-meal = 140 - 180

Special Note: More frequent daily monitoring should be done if started on steroids.

Oral Diabetes Medications

Start the following new diabetes medications:

Always try to include Gliptins [DPP4 Inhibitors] in the treatment regimen [Eg: Tab Vildagliptin / Sitagliptin] at the appropriate doses

Insulin Injections:

Start the following new insulin regimen Basal - Bolus:

Basal Insulin Regular Scheduled [Fixed] Dose TID + Sliding Scale Dose TID [Before Breakfast, Lunch and Dinner; Basal Insulin NPH or Glargine: After Dinner – Bedtime:



[Choose the appropriate Sliding Scale: Low – Mid – High]

liding Scale Choices Insulin Units:			TDD= Total Daily Dose given on previous day				
TDD	Scale	BG < 150	151-200	201-250	251-300	> 300	
< 40	Low	0	2	4	6	8	
41-80	Mid	0	3	6	9	12	
> 80	High	0	4	8	12	16	

Dose Titration: Daily calculate the Total Daily Dose of Insulin [TDD] and upgrade or downgrade the Scheduled Insulin Doses

	Dose Insulin Units: Ra	itio oi bolus : Bas	Sal = 2 : 2	: 2 : 1 [Exa	mple below]
TDD	Insulin Units	Breakfast	Lunch	Dinner	Bedtime
Bolus	Regular	8	8	8	0
Basal	NPH / Glargine	0	0	0	4

4: Sick / ICU diabetes patients with severe hyperglycaemia, DKA or HHNK:

Blood Glucose Monitoring

Frequency: Seven tests per day

Timings: Fasting; Before and 2 hours After Meals; 3 am

Blood Glucose Targets mg/dl: Pre-meal= 80 to 120; Post-meal = 140 - 180

Special Note: More frequent daily monitoring should be done if started on steroids.

Oral Diabetes Medications

Start the following new diabetes medications:

Always try to include Gliptins [DPP4 Inhibitors] in the treatment regimen [Eg: Tab Vildagliptin / Sitagliptin] at the appropriate doses

Insulin Injections:

Start the following new insulin regimen Basal - Bolus:

Basal Insulin Regular Scheduled [Fixed] Dose TID + Sliding Scale Dose TID [Before Breakfast, Lunch and Dinner;

Basal Insulin NPH or Glargine: After Dinner - Bedtime:

[Choose the appropriate Sliding Scale: Low - Mid - High]

liding Scale	Choices Insul	in Units:	TDD= Tota	Daily Dose giver	n on previous o	day
TDD	Scale	BG < 150	151-200	201-250	251-300	> 300
< 40	Low	0	2	4	6	8
41-80	Mid	0	3	6	9	12
> 80	High	0	4	8	12	16

Dose Titration: Daily calculate the Total Daily Dose of Insulin [TDD] and upgrade or downgrade the Scheduled Insulin Doses

Scheduled Dose Insulin Units: Ratio of BOLUS: BASAL = 2 : 2 : 2 : 1

TDD	Insulin Units	Breakfast	Lunch	Dinner	Bedtime
Bolus	Regular	8	8	8	0
Basal	NPH / Glargine	0	0	0	4



5: Intravenous Insulin use

Indications for Intravenous Insulin Infusion

1. Patients with nothing by mouth (NPO) status or those having erratic diet pattern (in time and content); 2. Diabetic keto-acidosis (DKA); 3. Uncontrolled hyperglycaemia despite Basal Bolus Regimen [Protocol 4]; 4. Severe hyperglycaemia at onset (Pre-meal BG level ≥300 mg/dl and post-meal BG level; ≥400 mg/dl); ketone status should be checked before starting infusion; 5. Critically ill like in sepsis and septic shock

Insulin Infusion Protocol:

Initiation: Insulin can be initiated at dose of 0.05-0.1 units/kg body weight/hour.

Infusion preparation: 50 units of regular insulin in 50 ml NS (1 unit / ml).

Frequency of blood glucose monitoring: 1 - 22 hourly; Can be extended to 4 hourly, where requirement is low, glucose values are stable and in target.

Glycaemic targets: To achieve and maintain blood glucose of 140 to 180 mg/dl for most individuals. BG target can be tightened to 110-180 mg/dl in a scenario where this target can be achieved without causing significant hypoglycemia and relaxed to 200-220 mg/dl where even a target of 140-180 mg/dl is unsafe and associated with increased risk of hypoglycemia.

6: Steroid - Glucocorticoid Therapy - Special precautions

Oral or Intravenous Steroid use

Please split total daily IV or Oral steroid dose into two doses, first before breakfast, second before dinner; this will help achieve a flatter / stable 24-hour glucose profiles

Discharge Criteria

The existing guidelines for discharge from the hospital vide reference above (IV) shall befollowed and the link is https://covid19.karnataka.gov.in/storage/pdf-files/cirhws/Revised%20Discharge%20Policy%20for%20COVID-19%20(Version%203).pdf

For asymptomatic individuals :

- All cases shall undergo regular temperature and pulse oximetry checks
- They shall be discharged if the following criteria is met at time of discharge;
 - No symptoms
 - No fever (recorded temperature≤37.5° or ≤99.5° F)
 - Maintains saturation above 95%
 - Respiratory rate less than 24 per minute.
- Asymptomatic individuals with a positive COVID-19 test report, who
 continues to remain asymptomatic during their stay in the hospital, <u>shall be</u>
 discharged 10 days after the positive test for COVID-19
 - For example, if swab wa collected on 1st august 2020 and tested positive for COVID-19, then the patients shall be discharged after 10



days from the date of swab collection i.e on11th August 2020. It is important that during this period, the patient shall remain free of any symptoms.

- There is no need for RT-PCR/CBNAAT/TruNAT test before discharge of the patient
- At the time of discharge, the patient will be advised to isolate himself at home and self- monitors their health for further 7 days.
- His /her health will again be followed up through tele-conference on14th day.
- After discharge from the facility, if he/she again develops symptoms of fever, cough or difficulty in breathing, he/she will contact the hospital or Apthamithra helpline 14410 immediately.

2. For Mild and Moderate cases:

- All cases shall undergo regular temperature and pulse oximetry checks.
- The patient <u>shall be discharged after 10 days of onset of symptom /s</u> only if the following criteria is met:
 - No Fever and No Symptom/s for the last 3 consecutive days before discharge (without antipyretics)
 - Maintains saturation above 95% for the last 4 consecutive days (without oxygen support)
 - Resolution of breathlessness
 - Resolution of clinical signs / symptoms (based on the report of investigations)
 - Repeat inflammatory markers (S.Ferritin, S.LDH, D-Dimer & CRP) at the time of discharge. These should be in normal range/decreasing trend
- For example, if a patient developed symptoms on 1st August 2020 and tested positive for COVID-19,
 - Example 1: If patient had symptoms for 1-7 days, the patient shall be discharged after 10 days from date of onset of symptoms i.e on 11th August 2020 (minimum 10 days for all symptomatic patients)
 - Example 2: If patient had symptoms for 14 days, the patient shall be discharged after 14 days + 3* days = 17 days from date of onset of symptoms, i.e on 17th August 2020 (* no Symptom/s for the last 3 consecutive days before discharge)
- There is no need for RT-PCR/CBNAAT/True-NAT test before discharge of the patient
- At the time of discharge, the patient will be advised to isolate himself at home and self-monitor their health for further 7 days.



3. For persons in Home isolation/ Home care

- Patient under home isolation will stand discharged (released from home isolation/ home care) after 10 days of symptom onset (or date of sampling, for asymptomatic cases) and no fever for 3 days. Thereafter, the patient shall be advised to isolate at home and self-monitor their health for further 7 days. There is no need for testing after the home isolation period is over
- They shall be released if the following criteria are met:
 - No symptoms
 - No fever (recorded body temperature ≤ 37.5°C or ≤99.5°F)
 - Maintains oxygen saturation above 95%
 - Respiratory rate less than 24 per minute
- There is no need for any COVID-19 test (RT-PCR/CBNAAT/True-NAT/Rapid Antigen test) after the period of home isolation/home care is over
- The person shall be allowed to resume duty only after satisfactory completion of home isolation/ home care

A fitness certificate shall be issued by the concerned area medical officer (PHC/UPHC/CHC/GH)/ treating physician/family doctor. Alternatively, an e-certificate may be issued in the prescribed format by tele-monitoring team

Transfer of clinically improved patients from COVID hospitals to COVID-19 Care Centres(CCCs)

o In view of surge in COVID-19 cases in the state and to ensure prudent use of hospital beds both in government and private for moderately and severely ill COVID-19 patients, it is necessary to transfer clinically improved patients to COVID Care Centres (CCCs) as per criteria mentioned below:

o No Fever and No Symptom/s for the last 3 consecutive days (without antipyretics) before transfer to CCC, and

o Maintaining oxygen saturation above 95% for the last 4 consecutive days (without oxygen support)

Those who fulfil these criteria in the COVID hospitals shall be transferred to the CCC by the treating physician after a careful clinical evaluation of the patient.

The above guidelines of admission, discharge, and transfer shall be followed in all DCHCs, DCHs, both in government and private in the state.

